Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer

NCT06197581 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT06197581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06197581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Not applicable
Overall status
Recruiting
Start date
January 12, 2024
Completion date
January 15, 2027
Enrollment
148 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, familial male, cdk4/6 inhibitor, chemotherapeutic toxicity, immune checkpoint inhibitor, parp inhibitor, pertuzumab, radiotherapy; complications, trastuzumab